The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Metastatic seeding in clinically undetectable primary CRC
Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA, talks on metastatic seeding in clinically undetectable primary colorectal cancer (CRC). Prof. Lenz discusses the possibility of using next-generation sequencing (NGS) to test primary tumors and predict if they are metastatic, rather than the current approach of using liquid biopsies to detect minimal residual disease (MRD). The potential to be able to identify a molecular signature present in the primary tumor at the time of diagnosis and know if a tumor is metastatic or not and the implications of this are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Ad Boards/Lectures: BMS, Roche, Oncocyte, Fulgent, Bayer, G1 Therapeutics, Jazz Therapeutics, Abbvie, Merck, Merck KG, Isofol
Clinical Trial Support: NCI, NIH, SWOG, Isofol, Pfizer, BMS, G1 Therapeutics, Cardiff, Amal-KISIMA, Mirati, Merck, Bayer, Idera, UCB, PsOxius, NGM, OBI Pharma
